<DOC>
	<DOCNO>NCT00377429</DOCNO>
	<brief_summary>The purpose study determine whether investigational drug catumaxomab deliver planned treatment schedule safe effective treatment woman advance ovarian cancer experience complete response chemotherapy .</brief_summary>
	<brief_title>Safety Efficacy Study Catumaxomab Treat Ovarian Cancer After Complete Response Chemotherapy</brief_title>
	<detailed_description>A multi-center , phase II study catumaxomab ovarian cancer patient experience complete response chemotherapy . Each eligible patient receive four ascend dos catumaxomab , administer intraperitoneally via indwell catheter port . Catumaxomab administer 3-hour constant rate infusion dose interval 3-4 day . Each patient participate study 4 month ( include baseline screen period , 11 21 day treatment period , 90 days/3 month follow-up ) , post-study follow-up every 3 month 2 year . Catumaxomab trifunctional antibody target epithelial cell adhesion molecule ( EpCAM ) tumor cell CD3 ( cluster differentiation 3 ) T cell . Trifunctional antibody represent new concept target anticancer therapy . This new antibody class capability redirect T cell accessory cell ( e.g . macrophage , dendritic cell [ DCs ] natural killer [ NK ] cell ) tumor site . According preclinical data , trifunctional antibody activate different immune effector cell , trigger complex anti-tumor immune response .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Antibodies , Bispecific</mesh_term>
	<criteria>Signed date informed consent form protocolspecific screening procedure Histologically confirm diagnosis epithelial ovarian cancer , fallopian tube , primary peritoneal cancer , Fédération Internationale de Gynécologie et d'Obstétrique ( FIGO ) stage IIb IV Optimal suboptimal cytoreductive surgery Clinical complete response platinum taxanebased therapy consist least four cycle , base compute tomography ( CT ) scan CA125 ( cancer antigen 125 ) level 35 U/mL Age ≥18 year Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Last dose platinum taxanebased therapy complete within 6 week prior start catumaxomab treatment Negative serum pregnancy test result screen woman childbearing potential ( applies patient without document menopause sterility ) Willingness patient childbearing potential use effective contraceptive method ( i.e . oral contraceptive , cervical cap , diaphragm spermicide , condom spermicide , intrauterine device ) study least 6 month last infusion Acute chronic systemic infection Exposure chemotherapy , radiotherapy , immunotherapy investigational anticancer therapy within 6 week first dose catumaxomab last regimen platinum taxane chemotherapy outline protocol Known human immunodeficiency virus ( HIV ) infection Previous treatment nonhumanized murine ( rat mouse ) monoclonal antibody ( mAb ) Inadequate renal function ( creatinine &gt; 1.5 x upper limit normal [ ULN ] ) Inadequate hepatic function : Alanine aminotransferase ( ALT ) &gt; 2.5 x ULN Aspartate aminotransferase ( AST ) &gt; 2.5 x ULN Bilirubin &gt; 1.5 x ULN Platelets &lt; 100,000 cells/mm^3 Absolute neutrophil count ( ANC ) &lt; 1,500 cells/mm^3 History myocardial infarction , congestive heart failure relevant cardiac arrhythmia within last 6 month No malignancy within past 5 year except nonmelanoma skin cancer carcinoma situ cervix adequately treat No history brain metastases Any condition disease would , opinion Investigator , expose patient undue risk</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Epithelial Cancer</keyword>
	<keyword>Epithelial Carcinoma</keyword>
	<keyword>Epithelial Ovarian Cancer</keyword>
	<keyword>Epithelial Ovarian Carcinoma</keyword>
	<keyword>Fallopian Tube Cancer</keyword>
	<keyword>Fallopian Tube Carcinoma</keyword>
	<keyword>Ovarian Cancer</keyword>
	<keyword>Ovarian Carcinoma</keyword>
	<keyword>Ovarian Epithelial Cancer</keyword>
	<keyword>Ovarian Epithelial Carcinoma</keyword>
	<keyword>Peritoneal Cancer</keyword>
	<keyword>Peritoneal Carcinoma</keyword>
	<keyword>Advanced Epithelial Ovarian Cancer</keyword>
</DOC>